New User:

Forgot your password?

Stock Market & Financial Investment News

News For ACAD From The Last 14 Days
Check below for free stories on ACAD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
10:10 EDTACADHigh option volume stocks
Subscribe for More Information
09:24 EDTACADACADIA management to meet with JPMorgan
Meetings to be held in Baltimore on September 17 and in New York on September 18 hosted by JPMorgan.
September 3, 2014
11:34 EDTACADACADIA price target raised to $28.50 at Ladenburg after breakthrough status
Subscribe for More Information
September 2, 2014
09:03 EDTACADACADIA receives FDA breakthrough therapy designation for Nuplazid
ACADIA Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinsonís disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinsonís disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application. ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use